Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 14, 2014; 20(30): 10331-10337
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10331
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10331
Ref. | Study design (level of evidence)1 | n | Helicobacter pylori positivity | Intervention | Outcome measure | Effect of eradicaction treatment |
Benvenga et al[20] | Crossover study (4) | 6 | Serology | Eradication tx vs placebo | AUC of | 21% increase after eradication treatment |
L-dopa | No variation after placebo | |||||
Pierantozzi et al[10] | RCT (1) | 34 | Serology, stool test, CP-test or culture | Eradication tx vs antioxidant tx (allopurinol) | AUC of | 54% increase after eradication treatment |
L-dopa | No variation after antioxidant tx | |||||
Lee et al[11] | Case series (3) | 65 | Urea breath test | Eradication tx | UPDRS-III | No variation |
L-dopa "onset" and "on-time" | 25.9% decrease and 11.9% increase after eradication tx |
-
Citation: Lahner E, Virili C, Santaguida MG, Annibale B, Centanni M.
Helicobacter pylori infection and drugs malabsorption. World J Gastroenterol 2014; 20(30): 10331-10337 - URL: https://www.wjgnet.com/1007-9327/full/v20/i30/10331.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i30.10331